Have you worked with MSF and would like to join as a member? Learn more!

Buenaventura’s Tuberculosis Trail

31.10.13
 MWA_OFFICER

In Buenaventura, port city of the Colombian Pacific coast, TB cases are three times higher than in the rest of Colombia. The failures of the health system impede access to appropriate care, and once obtained the drugs side effects and duration of treatment are new obstacles to recovery. Since 2010, MSF supports the National Programme against Tuberculosis to improve the diagnosis and treatment of the disease in the city of Buenaventura.

Along the road leading down into Buenaventura, the crisp air of the Andean peaks warms gradually, giving way to the moist Pacific climate. The barrios extend along both sides of Simon Bolivar Avenue, the main artery dividing the city and that leads to the country’s largest port. The goods circulating and the general bustle hide a high unemployment rate and precarious living conditions. The city has another important characteristic: a high prevalence of tuberculosis,[1] fostered by poverty.  “The incidence[2] of tuberculosis in Buenaventura is three times higher than that in the rest of the country,” explains Luis Fernando Jiménez Abelló, TB manager for Médecins Sans Frontières in Buenaventura. “And what’s most striking is the percentage of people who develop a resistant form of the disease in the primary infection phase.”

The system’s problems and weaknesses

“Tuberculosis is seen as a political issue, rather than being managed as a public health problem,” says Jiménez Abelló. “The authorities lack the will to improve treatment because they have other interests.” The city’s development follows two separate tracks. The port authority, which operates under the town’s auspices, just purchased five cranes at $25 million each. However, investment in public health is at a virtual standstill.

Here in the lobby of Buenaventura’s luxurious Hotel Torre Mar, the city’s busy health director, Dr. David Caicedo, leaves the workshop he is attending to answer questions. “The national authorities are not aware of the extent of the tuberculosis problem in Buenaventura,” he says. “There are major weaknesses in the Colombian health system and in TB treatment - specifically a lack of trained workers - but I’m still confident.”  His rhetoric is encouraging, but it does not reflect reality. Few initiatives are actually underway.

The plethora of actors involved in diagnosis and treatment delivery feeds confusion and creates inefficiencies in the health care system, which has been weakened by the cost of treatment and the lack of certain drugs at the national level.

“Between May and July of this year, we ran out of the main drug used in the intensive phase (the first two months) of treating regular TB,” Jiménez Abelló says.  “Given that we know that stock-outs promote the development of drug resistance, we can call this a health emergency.”

Treatment and side effects

Several patients wait their turn at the entry to the Independencia health center, which specializes in tuberculosis. Everyone here is required to wear a mask. Further along the hallway, the door to a room on the right is half-open. This is where patients with a form of drug-resistant tuberculosis come every day for treatment. Some forty containers are stacked in the cupboard on the left side of the room. Each is labeled with a first name - Maria José, Carlos, Jaime and many more. “Each container corresponds to a patient’s treatment,” Jiménez Abelló explains. The treatment is called DOTS, for directly observed therapy.  Patients must take their medicine every day as a health care worker watches.” A young girl is taking her drugs. Using her finger, she points out the order in which she wants to take each medication. As she works her way through them, the time between swallowing each pill lengthens, she takes an ever-larger gulp of water and the grimace on her face becomes more pronounced. “I take 20 pills every day – each one is a different size, color and texture.” This is an XDR patient. She suffers from an extensively drug-resistant form of tuberculosis.     

The treatment is complicated, particularly because it produces many side effects. Maria Victoria completed her treatment five months ago. She recalls the process. “I had a lot of headaches and stomach aches. I lost my appetite and I felt very weak. Sometimes I couldn’t even keep down a glass of water.” 

Tuberculosis is a contagious infectious disease. There is no vaccination and the clinical signs of the illness vary.  It is caused by a mycobacterium tuberculosis complex composed of many bacteria, primarily the Mycobacterium tuberculosis (Koch’s bacillus).  Drug-sensitive TB can be treated in a few months, but treating a drug-resistant form can take more than two years.  

Stigmatization and isolation

TB patients in Buenaventura are still stigmatized. One patient, Elix Marina, says, “I think people here are more afraid of tuberculosis than of HIV/AIDS. I don't understand why.”  Many patients confide that they suffer from the community’s attitude and experience rejection and isolation. “I didn’t leave my house,” Maria Victoria says. “I only went from the house to the health center. When I was in the street, I didn’t look at anyone. Very few people dared to touch me.” This 45-year old patient completed her treatment just five months ago and becomes emotional when she remembers these painful moments.  However, family support can help ensure successful treatment. It is critical to encouraging patients to continue with treatment.

“This may be due to the method of transmission or the fact that a person with TB is readily identifiable because of the mask,” says Juan Carlos Arteaga España, the MSF project psychologist. “But most importantly, I think there is a lack of information and education about this disease.”  

A multidisciplinary approach

The length of treatment, the daily regimen of pills, alcohol and drug dependency and stigmatization lead certain patients to abandon treatment. The many side effects are also discouraging. Maria de los Angeles is an example. One of the wooden walls in her house is gone. When Karol, the Médecins Sans Frontières social worker, asks her if water comes in when it rains, she simply says, “No, not through the wall or through the door, which is always open.” Maria de los Angeles was one of the patients whose TB treatment MSF monitored – before she abandoned treatment. “The side effects were unbearable,” she says. “I hurt everywhere. I couldn’t go on like that.”           

To encourage drug-resistant patients to comply with their treatment, MSF offers a comprehensive, multi-disciplinary treatment approach that combines medical, psychological and social support. “Patient support plays an important role in minimizing treatment abandonment,” Jiménez Abelló explains. “Organization also plays an important role in early detection and diagnosis of TB cases. The team simultaneously monitors 15 public and private health care facilities that treat drug-sensitive TB patients.

MSF launched its TB treatment program in Buenaventura nearly three years ago. This year, the first patients with drug-resistant TB completed their treatment. “When they told me that the treatment was over and that I was well, I turned everything upside down at the health center! I screamed, I cried, I hugged and I thanked all the medical staff. I went down on my knees.” Maria Victoria remembers the emotion and sense of relief she felt when she completed her treatment just five months ago. “It was like I had returned to life.”




[1] Prevalence is the number of individuals in a population who have a particular disease at a given time, regardless of when they became ill. 

[2] Incidence is the number of new cases – the number of people who acquire an illness during a given period in a given population. In other words, it refers to the number of annual new cases of the disease.